InMed Pharmaceuticals Inc (OTCMKTS:IMLFF) Provides Updates For Its 1Q20

InMed Pharmaceuticals Inc (OTCMKTS:IMLFF) Provides Updates For Its 1Q20

InMed Pharmaceuticals
is pleased to pronounce its financial results. These
are for the fiscal year 2020 and specifically the first-quarter performance.

A close look at the

 Investors in the
company will need to take a close look at the financial results reported for
the three months. That is the only way to make informed decisions regarding
investments according to analysts.

The President and Chief Executive Officer of InMed
Pharmaceuticals Eric A. Adams is one of the leaders that has spoken about the
performance. He commends the company for the progress it made in the first

The turn of events

 The company
successfully submitted its Clinical Trial Application to the regulatory bodies.
It sought to obtain a nod to engage in a series of human clinical trials. It
would be utilizing INM-755 in the undertaking upon getting permission.

Adams is pleased about the company’s progress so far and has
termed it meaningful. Focus is currently on areas such as the company’s lead
programs, one of them being the biosynthesis manufacturing platform. The others
are INM-088 and INM-755 for EB in glaucoma. This leader says that they will
keep updating investors about their progress regularly. This business guru
remains focused on its North American investment communities. It also seeks to
pull in more of the international investment communities.

The company’s chief executive officer says there has been an
increase in the research and development segments. This is from a figure of
about $0.63 million for the three last months of 2018 to $2.33 million for
1Q20. He attributed the increase in expenditure on what was spend on INM-755
for the clinical trial. According to the official, it was a major boost to both
the toxicology and the pharmacology studies.

These studies can’t be taken for granted because they are
the cornerstone in the regulatory filing. Without them, it would be almost
impossible to kick-start the human clinical trials cut out to commence soon.

This company admits that it spent quite a large sum much in
buying its active pharmaceutical ingredients in INM-755. This had to be done in
advance before the commencement of the company’s much anticipated clinical

Published at Thu, 14 Nov 2019 13:58:29 +0000

Leave a Reply

Your email address will not be published. Required fields are marked *